Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This phase III trial compares the effect of bevacizumab and osimertinib combination vs.
osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of
the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein
is involved in cell signaling pathways that control cell division and survival. Sometimes,
mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on
some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may
stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type
of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of
tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for
longer and help patients live longer as compared to osimertinib alone.